未登录

S

Shengping Li

Sun Yat Sen University

H指数:31

被引数:3,296

个人简介

暂无内容

教育背景

暂无内容

工作经历

暂无内容

荣誉奖项

暂无内容

Fluorinated Bismaleimide Composites with Enhanced Piezoelectric Characteristics for Motion Monitoring

含氟双马来酰亚胺复合材料，具有增强的压电特性，用于运动监测

ACS Applied Polymer Materials

IF4.7

2025-10-150

PRE

Heterogeneous interfaces constructing endogenous triboelectric effect to enhance output performance of intelligent sensor

构建异质界面以产生内生三电极效应，进而增强智能传感器的输出性能

Chemical Engineering Journal

IF13.2

2025-07-290

PRE

Red mud utilization in fiber-reinforced 3D-printed concrete: Mechanical properties and environmental impact analysis

纤维增强3D打印混凝土中的赤泥利用：力学性能和环境影响的评估分析

CONSTRUCTION AND BUILDING MATERIALS

IF8

2025-02-011

PRE

Development of a Nomogram Integrating Modified Inflammation-Based Indexes for Predicting Overall Survival in Pancreatic Cancer: A Retrospective Study

基于改良炎症指标的列线图预测胰腺癌总生存期的回顾性研究

inflammation research

IF4.1

2025-01-010

OA

Unexpected piezoelectric properties of electrospun polyimide nanofibers for application in an extreme environment

用于极端环境的电纺聚酰亚胺纳米纤维的意外压电性能

Journal of Materials Chemistry C

IF5.1

2025-01-012

PRE

Multimodal single cell-resolved spatial proteomics reveal pancreatic tumor heterogeneity

NATURE COMMUNICATIONS

IF15.7

2024-11-210

OAAI

Combining NanoKnife with M1 oncolytic virus enhances anticancer activity in pancreatic cancer (vol 502, pg 9, 2021)

IF10.1

2024-05-010

OAAI

Efficacy and safety of SOXIRI versus mFOLFIRINOX in advanced pancreatic cancer

THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY

IF4.2

2023-07-082

OAAI

Establishment and validation of a prognostic signature for pancreatic ductal adenocarcinoma based on lactate metabolism-related genes

FRONTIERS IN MOLECULAR BIOSCIENCES

IF4

2023-06-091

OAAI

A Cyclodiaryliodonium NOX Inhibitor for the Treatment of Pancreatic Cancer via Enzyme-Activatable Targeted Delivery by Sulfated Glycosaminoglycan Derivatives

ADVANCED HEALTHCARE MATERIALS

IF9.6

2023-03-1610

PRE

Serum Amyloid a Predicts Prognosis and Chemotherapy Efficacy in Patients with Advanced Pancreatic Cancer

inflammation research

IF4.1

2023-03-015

OA

RETRACTION: miR-3928v is induced by HBx via NF-κB/EGR1 and contributes to hepatocellular carcinoma malignancy by down-regulating VDAC3 (vol 37, 14, 2018) (Retraction of Vol 39, Pg 165, 2020)

JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH

IF12.8

2022-12-280

OAAI

Cisplatin and gemcitabine exert opposite effects on immunotherapy with PD-1 antibody in K-ras-driven cancer

JOURNAL OF ADVANCED RESEARCH

IF13

2022-09-0122

OAAI

Multimodal data analysis reveals that pancreatobiliary-type ampullary adenocarcinoma resembles pancreatic adenocarcinoma and differs from cholangiocarcinoma

JOURNAL OF TRANSLATIONAL MEDICINE

IF7.5

2022-06-154

OAAI

An Inflammatory Response-Related Gene Signature Reveals Distinct Survival Outcome and Tumor Microenvironment Characterization in Pancreatic Cancer

FRONTIERS IN MOLECULAR BIOSCIENCES

IF4

2022-06-087

OAAI

The enhanced cell cycle related to the response to adjuvant therapy in pancreatic ductal adenocarcinoma

IF3

2022-01-010

OAAI

RETRACTION: miR-639 Expression Is Silenced by DNMT3A-Mediated Hypermethylation and Functions as a Tumor Suppressor in Liver Cancer Cells (Retraction of Vol 28, Pg 587, 2020)

MOLECULAR THERAPY

IF12

2022-01-010

OA

RETRACTION: HBV-encoded miR-2 functions as an oncogene by downregulating TRIM35 but upregulating RAN in liver cancer cells (Retraction of Vol 48, Pg 117, 2019)

IF10.8

2021-10-010

OA

Irreversible Electroporation Plus Anti-PD-1 Antibody versus Irreversible Electroporation Alone for Patients with Locally Advanced Pancreatic Cancer

inflammation research

IF4.1

2021-09-0118

OA

RETRACTION: A novel microRNA identified in hepatocellular carcinomas is responsive to LEF1 and facilitates proliferation and epithelial-mesenchymal transition via targeting of NFIX (Retraction of Vol 7, art no 22, 2018)

IF6.4

2021-07-150

OAAI